Rebordosa C, Thomsen RW, Tave AK, Madsen M, et al. Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohorts. Diabetes Obes Metab 2024 Jan 17. doi: 10.1111/dom.15429.
PMID: 38234181